Biota Pharmaceuticals, Inc. (BTA.AX)
-ASX | Prev Close: | 0.57 |
|---|
| Open: | 0.60 |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.57 - 0.61 |
|---|
| 52wk Range: | 0.57 - 0.86 |
|---|
| Volume: | 6,535,349 |
|---|
| Avg Vol (3m): | N/A |
|---|
| Market Cap: | N/A |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in AUD.
Headlines
- Mesoblast may list on Nasdaqat Reuters(Tue, Apr 2)
- Nabi Biopharmaceuticals Effects Reverse Stock Split and Announces the Completion of and Final Exchange Ratio for the Business Combination Transaction With Biota Holdings Limitedat Reuters(Fri, Nov 9)
- Biota Receives $4.2m R&D Tax CreditMarketwired(Wed, Nov 7)
- Nabi Biopharmaceuticals Announces Nabi Stockholder Meeting Results and the Approval of the Business Combination Transaction by Biota Stockholdersat Reuters(Tue, Oct 23)
- Biota Announces Shareholder Approval of Merger With Nabi PharmaceuticalsMarketwired(Tue, Oct 23)
- Biota Announces Approval of Definitive Merger Agreement by Nabi ShareholdersMarketwired(Tue, Oct 23)
- Nabi Biopharmaceuticals Announces Exchange Ratio for Proposed Business Combination Transaction With Biota Holdings Limitedat Reuters(Fri, Oct 19)
- Nabi Biopharmaceuticals Sets Record Date for Cash Dividendat Reuters(Tue, Oct 16)
- Two Major Independent Proxy Advisory Firms Recommend Nabi Biopharmaceutical Stockholders Support Amended Transaction With Biota Holdings Limited at October 22nd Reconvened Special Meetingat Reuters(Tue, Oct 16)
- Nabi Biopharmaceuticals Announces Adjournment of Special Meeting of Stockholders Until October 22, 2012at Reuters(Mon, Sep 24)
- Biota and Nabi Announce Revised Merger TermsMarketwired(Tue, Sep 18)
- Biota Announces Inavir Achieves Primary Endpoint in Phase III Prevention StudyMarketwired(Wed, Aug 22)
- Biota Shareholders Meeting on Proposed Merger With NabiMarketwired(Thu, Aug 9)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(0-00-31)
: | N/A |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Biota Pharmaceuticals, Inc. engages in the drug discovery and clinical development of anti-infectives in Australia. It offers zanamivir, a neuraminidase inhibitor for the treatment and prophylaxis of influenza; and laninamivir for the treatment of...
View More 
0.12%